Positive Dynamics of Microfluidic-Based Point-of-Need
Product News Mar 06, 2018
PoN market growth is driven mainly by PoC applications (human diagnostics), which enable the rapid analysis of patients’ samples out of reference laboratories, in a decentralized way. Therefore, PoC diagnostics allow patients to receive an appropriate treatment faster, and reduce costs by lowering the duration and frequency of a hospital stay. Some tests are also used to monitor a patient’s condition over time.
In this context, the market research and strategy consulting company, Yole Développement (Yole) announces a US$4 billion microfluidic market for PoN testing applications in 2017 with a 23% growth rate year-over-year by 2023. According to its analysts, the microfluidic market for PoN testing should reach around US$13.2 billion at the end of the period. “This impressive growth will be driven by a high interest from IVD companies for PoN solutions” asserts Asma Siari, Technology & Market Analyst at Yole. “In addition, investors will also play a key role through strong investments in decentralized testing technologies”.
Yole’s vision of microfluidics-based PoN market is available today in the new report titled “Point-of-Need Testing: Application of Microfluidic Technologies”. This analysis provides a complete update of the PoN market data, drivers for each segment, key technical and economic requirements and prospects of the microfluidic industry for PoN diagnostics applications. In parallel, Yole’s report proposes a comprehensive analysis of the relationship between potential PoN applications, emerging technologies and microfluidics assets. Market segmentation including main players and product examples per segment, along with market share is also well analyzed in this new report as well as regulatory, market access, and reimbursement landscape in human, veterinary, and agro-food markets in the USA, Europe, and China.
Positive dynamics including strong investments, more than 15 new products and clinical validations are analyzed. Yole’s analysts invite you to learn more about the status of this market.
Since 2016, the market research & strategy consulting company Yole has identified more than US$10 billion of investments in different acquisitions between large diagnostic companies: for example, Abbott, which acquired a large part of Alere (including diagnostic solutions for diabetes, lipid disorders, and molecular testing for infectious diseases) for an impressive amount of US$5.3 billion. More recently, in January 2018 Qiagen acquired STAT Dx for US$191 million. This acquisition gives to Qiagen control of STAT Dx’s respiratory and gastrointestinal diseases pipeline.
Moreover, microfluidic companies developing PoN testing solutions have raised more than US$650 million since 2016, and the pace at which new products are being commercialized is accelerating.
The PoN market encompasses a wide range of products used by healthcare professionals and untrained users; while the processes embedded into the test cartridges are increasingly complex, these are designed to be always easier to use. In this report, Yole’s analysts explore the technologies used across different market segments, highlight the reasons why such technologies are used, and discuss how they evolve. “In the long-term, advances in miniaturization, batteries, and molecular diagnostics will see POC microfluidic tests proliferate beyond the traditional care settings of hospitals and doctor’s offices, towards home use, representing a market value of US$129 million by 2023”, comments Sébastien Clerc, Technology & Market Analyst at Yole. Also, emergency testing and third-world testing will remain the largest segments in terms of volume of microfluidic-based consumables, reaching 211 million units and 196 million units by 2023, respectively.
In its new report, Yole also expects to see an increasing number of solutions from small startups and large diagnostic companies aimed at addressing veterinary, agro-food, environmental, and industrial testing segments. Indeed, these segments present different barriers and opportunities than human diagnostics and look increasingly attractive. Furthermore, PoN assay menus are quickly expanding, with many companies releasing several new tests every year. Historically, assays with more complex procedural steps were reserved for central labs to carry out, but recently PoN diagnostic companies have developed microfluidic technologies to integrate all the required steps into a single cartridge that can perform multiple tests in parallel. For example, many companies including Alere, Biocartis, bioMérieux, Cepheid, GenePOC, Roche, among others, have brought to market molecular diagnostic tests including sample preparation, amplification, and detection.
Some key PoN players are developing targeted tests allowing detection of a specific disease, while others are developing syndromic tests for the detection of a wide number of analytes: for example, bioMérieux (BioFire), which is developing tests for groups of diseases (a gastrointestinal panel, a respiratory panel, etc.). Further improvements in multiplexing, automation, and integration will drive the PoN market by enabling the development of increasingly complex tests on a simple microfluidic chip…